Eli Lilly Zepbound联用amylin药物eloralintide中期试验显示显著减重
STAT+: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial
Eli Lilly的GLP-1药物Zepbound与amylin激素靶点候选药eloralintide联用,在肥胖合并2型糖尿病患者中开展的中期研究显示,48周后维持最高剂量联用治疗组的参与者体重下降23.3%。这一结果高于单用Zepbound(14.8%)和单用最高剂量eloralintide(11.1%)的减重幅度。研究者指出,接受该联用治疗时停药率较高,可能影响对疗效的判读。
原文明确展示Zepbound与eloralintide联用在48周时达到的体重下降幅度,读者可据此比较单药与联用的减重效果。
![]()
By Elaine Chen
Sept. 30, 2026
Chen, a national biotech reporter, is the co-author of The Readout, a newsletter about the business, science, and politics of biotech.
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.
An investigational combination therapy from Eli Lilly led to significant weight loss in a mid-stage study, but high rates of people stopping the treatment may raise questions about its tolerability.
Lilly, which is racing to bring next-generation obesity drugs to the market, tested different combinations of its blockbuster GLP-1 drug Zepbound with eloralintide, a candidate that targets the amylin hormone, in people with obesity and type 2 diabetes.
After 48 weeks, participants who stayed on the treatment at the highest dose of the combination therapy lost 23.3% of their weight, according to results presented Wednesday at the annual meeting of the European Association for the Study of Diabetes. That’s more than the weight loss seen with those taking only Zepbound and those taking only the highest dose of eloralintide — 14.8% and 11.1%, respectively.
The results were also notable because patients with diabetes don’t tend to lose as much weight on medications as those who don’t have diabetes.
STAT+ Exclusive Story
Already have an account? Log in

This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
来源:STAT Pharma 医药频道 · statnews.com